Dutch Regulator Opens Antitrust Probe into Biogen
The Netherlands is investigating the company's Stratify test amid ongoing scrutiny from Italian authorities.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Do you trust that regulators effectively hold pharmaceutical companies accountable for anticompetitive behavior?
Dutch competition authorities have launched an antitrust investigation into Biogen concerning its Stratify test. This probe follows an ongoing regulatory inquiry into the same product by officials in Italy that began earlier this year.
Why it matters
The investigation highlights increasing regulatory scrutiny surrounding the market practices of pharmaceutical companies like Biogen. Ongoing legal pressure across multiple European jurisdictions suggests potential challenges for the company's competitive standing in the region.
The Dutch inquiry focuses specifically on the market deployment and competitive implications of the Stratify test. This follows a similar investigation initiated in Italy regarding an alleged abuse of dominant position against Sandoz.
The players
Biogen
Biogen is a global biotechnology firm that focuses on developing and delivering therapies for people living with serious neurological and neurodegenerative diseases.
Sandoz
Sandoz is a global pharmaceutical company that specializes in the development and manufacturing of generic and biosimilar medicines.
The details
Biogen officially disclosed the commencement of the Dutch investigation within a regulatory filing. The Italian regulatory body has been reviewing the same product line for potential market dominance abuses since mid-2026.
Timeline
May 2026: Italian regulators began their investigation into the Stratify test.
October 28, 2026: Biogen formally disclosed the new Dutch investigation in a regulatory filing.
The Tech Race
Regulatory scrutiny of medical technology companies increasingly mirrors efforts to curb monopolistic behavior within broader digital and tech sectors. By targeting the Stratify test, regulators are asserting that competitive compliance is as vital for biotech as it is for software platforms.
These investigations may eventually influence the availability or pricing of specialized diagnostic tests like Stratify. Consumers and medical providers should monitor regulatory updates, as outcomes could lead to changes in market competition and potential cost adjustments.
The takeaway
Antitrust investigations often signal long-term shifts in how companies must manage their competitive distribution strategies. Businesses in the biotech space should prioritize transparency to avoid similar regulatory oversight in major European markets.
Further reading
For more information on the evolving regulatory landscape, visit the Biotech section.
Source note: This article includes information reported by Mlex.
Live Poll
Do you trust that regulators effectively hold pharmaceutical companies accountable for anticompetitive behavior?
